title: Radiotherapy complements immune checkpoint blockade.
abstract: Adaptive immune resistance ablates effective anti-tumor immune responses. In a recent issue of Nature, Victor and colleagues describe that anti-PD-L1 combats adaptive immune resistance upon localized radiation plus anti-CTLA-4 therapy. The superior activity of radiation and dual immune checkpoint blockade is mediated by non-redundant immune mechanisms in cancer.
authors: Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Medicine, University of Queensland, Herston, QLD 4006, Australia.
authors: Shin Foong
authors: SF
authors: Ngiow
authors: Cancer Therapeutics Programs, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC 3002, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.
authors: Grant A
authors: GA
authors: McArthur
authors: Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Medicine, University of Queensland, Herston, QLD 4006, Australia. Electronic address: mark.smyth@qimrberghofer.edu.au.
authors: Mark J
authors: MJ
authors: Smyth
mesh_terms: D000818:Animals; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D059447:Cell Cycle Checkpoints / Q000187:drug effects*; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology* / Q000532:radiotherapy*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000528:radiation effects*
chemical_list: D060890:B7-H1 Antigen; D060908:CTLA-4 Antigen